Historically, head and neck squamous cell carcinoma (HNSCC) has been earmarked a lymphatic malignancy. Recently, this has been called into question. Our study aims to (1) illustrate the robust differences in distant metastases between p16+ and p16– oropharyngeal squamous cell carcinoma (OPSCC) and (2) provide support that p16+ OPSCC has a predilection toward vasculature invasion and hematogenous spread.
Study Design
Multi-institutional, case series with chart review.
Setting
Four academic institutions.
Subjects and Methods
Within a group of 1113 patients with primary OPSCC who received treatment between 1979 and 2013, those who developed distant metastasis (DM) were divided into 2 cohorts based on p16 status. Intergroup and intragroup univariate analysis was performed as well as descriptive analysis of end-organ sites.
Results
Of the 1058 patients included, 89 developed DM. Thirty were p16– and 59 were p16+. Of the p16– patients with DM, only 10% had disseminated disease (distant metastases at ≥2 sites) compared with 74% of p16+ patients. Distant disease in p16+ patients included brain, abdomen, and a distinct pattern of pulmonary metastases.
Conclusion
Our large, multi-institutional study supports published reports that p16+ OPSCC metastasizes with a unique phenotype that is hematogenous and widely disseminated with atypical end-organ sites. Our data suggest that p16+ OPSCC has a predilection toward active vasculature invasion as evidenced by the results and illustrative radiologic and pathohistologic examples. These findings may have implications for future targeted therapy when treating p16+ OPSCC.
WilhelmIMolnárJFazakasCHaskóJKrizbaiIA. Role of the blood-brain barrier in the formation of brain metastases. Int J Mol Sci. 2013;14:1383-1411.
5.
CrileG. Landmark article Dec 1, 1906: Excision of cancer of the head and neck. With special references to the plan of dissection based on one hundred and thirty-two operations. By George Crile. JAMA. 1987;258:3286-3293.
6.
IshibashiTMatsushimaSTsunokawaY. Human papillomavirus DNA in squamous cell carcinoma of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg. 1990;11:294-298.
7.
LeongSPCadyBJablonsDMGarcia-AguilarJ. Clinical patterns of metastasis. Cancer Metastasis Rev. 2006;25:221-232.
8.
KlussmannJPMoorenJJLehnenM. Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin Cancer Res. 2009;15:1779-1786.
9.
LohavanichbutrPHouckJFanW. Genomewide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: potential implications for treatment choices. Arch Otolaryngol Head Neck Surg. 2009;135:180-188.
10.
GillisonML. Human papillomavirus–associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004;31:744-754.
11.
VidalLGillisonML. Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin North Am. 2008;22:1125-1142.
12.
HuangSH1Perez-OrdonezBLiuFF. Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82:276-283.
13.
SinhaPThorstadWTNussenbaumB. Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomes. Oral Oncol. 2014;50:45-51.
14.
MullerSKhuriFRKonoSA. HPV positive squamous cell carcinoma of the oropharynx: are we observing an unusual pattern of metastases?Head Neck Pathol. 2012;6:336-344.
15.
MehradMCarpenterDHChernockRD. Papillary squamous cell carcinoma of the head and neck: clinicopathologic and molecular features with special reference to human papillomavirus. Am J Surg Pathol. 2013;37:1349-1356.
16.
AllenCTLawJHDunnGPUppaluriR. Emerging insights into head and neck cancer metastasis. Head Neck. 2013;35:1669-1678.
17.
TravisK. Bernard Fisher reflects on a half-century’s worth of breast cancer research. J Natl Cancer Inst. 2005;97:1636-1637.
18.
HuangSHPerez-OrdonezBWeinrebI. Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol. 2013;49:79-85.
19.
GillisonMLShahKV. Human papillomavirus–associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol. 2001;13:183-188.
20.
DeschlerDGRichmonJDKhariwalaSSFerrisRLWangMB. The “new” head and neck cancer patient-young, nonsmoker, nondrinker, and HPV positive: evaluation. Otolaryngol Head Neck Surg. 2014;151:375-380.
21.
ChungCHZhangQKongCS. p16 Protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol. 2014;32:3930-3938.
22.
WeinbergerPM1YuZHafftyBG. Molecular classification identifies a subset of human papillomavirus—associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006;24:736-747.
23.
HaugheyBHSinhaP. Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer. Laryngoscope. 2012;122:S13-S33.
24.
RamqvistT1DalianisT. Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis. 2010;16:1671-1677.
25.
RamqvistT1DalianisT. An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. Anticancer Res. 2011;31:1515-1519.
26.
DietlBMarienhagenJSchaeferCPohlFKölblO. Frequency and distribution pattern of distant metastases in patients with ENT tumors and their consequences for pretherapeutic staging. Strahlenther Onkol. 2007;183:138-143.
27.
MerinoORLindbergRDFletcherGH. An analysis of distant metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer. 1977;40:145-151.
28.
KotwallCSakoKRazackMSRaoUBakamjianVSheddDP. Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg. 1987;154:439-442.
29.
LimYCKooBSChoiEC. Bilateral neck node metastasis: a predictor of isolated distant metastasis in patients with oral and oropharyngeal squamous cell carcinoma after primary curative surgery. Laryngoscope. 2007;117:1576-1580.
30.
ShahSMDrageMGLichtmanAHHaddadRI. Metastatic human papillomavirus–positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread. J Clin Oncol. 2012;30:e321-e323.
31.
MaxwellJHKumarBFengFY. Tobacco use in human papillomavirus–positive advanced oropharyngeal cancer patients related to increased risk of distant metastases and tumor recurrence. Clinc Cancer Res. 2010;16:1226-1235.
32.
AndersenASKoldjaer SøllingASOvesenTRusanM. The interplay between HPV and host immunity in head and neck squamous cell carcinoma. Int J Cancer. 2013;134:2755-2763.
33.
HuangSHPerez-OrdonezBLiuFF. Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82(1):276-283.
34.
BoccaEPignataroOOldiniCCappaC. Functional neck dissection: an evaluation and review of 843 cases. Laryngoscope. 1984;94:942-945.
LeongPPRezaiBKochWM. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst. 1998;90:972-977.
37.
zur HausenH. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-350.
38.
LimMCLeeHSSeoSS. Pathologic diagnosis and resection of suspicious thoracic metastases in patients with cervical cancer through thoracotomy or video-assisted thoracic surgery. Gynecol Oncol. 2010;116:478.
39.
FulcerASO’SullivanSGSegretiEMKavanaughBD. Recurrent cervical carcinoma: typical and atypical manifestations. Radiographics. 1999;19:103-116.
40.
HaasbeekCJUitterhoeveALvan der VeldenJGonzalezDGStaplersLJ. Long-term results of salvage radiotherapy for the treatment of recurrent cervical carcinoma after prior surgery. Radiother Oncol. 2008;89:197.
41.
WilhelmIMolnárJFazakasCHaskóJKrizbaiIA. Role of the blood-brain barrier in the formation of brain metastases. Int J Mol Sci. 2013;14:1383-1411.
42.
HenriksenE. The lymphatic spread of carcinoma of the cervix and of the body of the uterus. Am J Obstet Gynecol. 1949;58:924-942.
43.
LefkowitzDAsconapeJBillerJ. Intracranial metastases from carcinoma of the cervix. South Med J. 1983;76:519-521.
44.
CormioGPellegrinoALandoniFRegalloMZanettaGColomboA. Brain metastases from cervical carcinoma. Tumori. 1996;82:394-396.
45.
YangLYangHWuKShiXMaSSunQ. Prevalence of HPV and variation of HPV 16/HPV 18 E6/E7 genes in cervical cancer in women in South West China. J Med Virol. 2014;86:1926-1936.
46.
WiltingSMSmeetsSJSnijdersPJ. Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Med Genomics. 2009;1:32.
47.
NeufeldGCohenTGengrinovitchSPoltorakZ. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22.
48.
Lopez-OcejoOViloria-PetitABequet-RomeroMMukhopadhyayDRakJKerbelRS. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene. 2000;19:4611-4620.
49.
ShemiraniBCroweDL. Head and neck squamous cell carcinoma lines produce biologically active angiogenic factors. Oral Oncol. 2000;36:61-66.
50.
TewariKSSillMWLongHJ. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734-743.
51.
Salomon-PerzyńskaMPerzyńskiARembielak-StaweckaB. VEGF-targeted therapy for the treatment of cervical cancer—literature review. Ginekol Pol. 2014;85:461-465.
